Ironwood Pharmaceuticals, Inc. · NASDAQ:IRWD
Ironwood Pharmaceuticals — FY2024 Earnings Presentation
19 slides from Ironwood Pharmaceuticals's earnings presentation, Feb 27, 2025
Slide 1: Q4 and FY 2024 Investor Update
Ironwood Pharmaceuticals Q4 and FY 2024 Investor Update February 27, 2025 *Figures on slides 6, 12, 15 and 16 have been adjusted as of March 31, 2025 1
Slide 2: Introduction
Introduction \\ Ironwood!
Slide 3: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about our ability to execute on our mi
Slide 4: Today's Agenda
Today’s Agenda • Introduction • Overview Tom McCourt, Chief Executive Officer • Pipeline Update Mike Shetzline, M.D., Ph.D., Chief Medical Officer • Commercial Update, Financial Highlights and FY 2025 Guidance Greg Martini, Chief Financial Officer 4
Slide 5: Overview
Overview Tom McCourt '\ Ironwood
Slide 6: Positioned for long-term success in GI and Rare Disease
Positioned for long-term success in GI and Rare Disease Advance Apraglutide First and only investigational once-weekly GLP-2 analog to successfully demonstrate positive Phase 3 results Streamlined Organization STARS represents largest Phase III trial in SBS-IF conducted to date. Positioned for L
Slide 7: Pipeline Update
Pipeline Update Mike Shetzline 7
Slide 8: There is high unmet need for SBS patients who are dependent on parenteral support
There is high unmet • Approximately 18,000 adult patients with short bowel syndrome who are dependent on parenteral support need for SBS patients across the U.S., Europe and Japan3 who are dependent on parenteral support (PS) • Patients with short bowel syndrome suffer from irreparable GI damage and
Slide 9: STARS Extend study data demonstrate more patients reduced parenteral support with longer exposure
STARS Extend study data demonstrate that more patients reduced parenteral support with longer exposure to apraglutide, with additional patients achieving enteral autonomy Days Off PS and Once-Weekly Convenience Advance Safety and Tolerability EnteralApraglutide Autonomy • Apraglutide is the only GLP
Slide 10: Commercial Update, Financial Highlights and 2025 Guidance
Commercial Update, Financial Highlights and 2025 Guidance Greg Martini 10
Slide 11: 2024 double-digit prescription (EUTRx) and new-to-brand (NBRx) growth
2024 double-digit prescription (EUTRx) and new-to-brand (NBRx) growth LINZESS EUTRx LINZESS NBRx 20.0 70,000 60,000 18.0 50,000 EUTRx Volume 16.0 NBRx Volume 40,000 Millions 30,000 14.0 20,000 12.0 10,000 10.0 0 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2022 2023 2024 NBRx Capture Date Began A
Slide 12: FY 2024 financial performance
FY 2024 financial performance $916.3M $351.4M LINZESS U.S. Net Sales1 Total Ironwood Revenue LINZESS U.S. net sales decreased 15% year-over-year. Strong prescription demand growth was more than offset by pricing headwinds $0.9M4 $99.5M4 GAAP Net Income2 Adjusted EBITDA2 $0.01/share – basic and dilut
Slide 13: We are maintaining our FY 2025 guidance
We are maintaining our FY 2025 guidance FY 2025 Guidance (February 2025) LINZESS U.S. $800 – $850 million net sales Ironwood revenue $260 – $290 million Adjusted EBITDA1 > $85 million 1 Adjusted EBITDA is calculated by subtracting restructuring expenses, net interest expense, income taxes, depreciat
Slide 14: Appendix
APPENDIX \\ Ironwood?
Slide 15: Q4 and FY 2024 Financial Summary
Q4 and FY 2024 Financial Summary Reconciliation of GAAP results to non-GAAP financial measures (page 1) Three Months Ended Twelve Months Ended December 31, 2024 December 31, 2024 (000s, except per share amounts) (000s, except per share amounts) GAAP net income1,2 $2,256 $880 Adjustments: Mark-to-mar
Slide 16: Q4 and FY 2024 Financial Summary
Q4 and FY 2024 Financial Summary Reconciliation of GAAP net income to adjusted EBITDA Three Months Ended Twelve Months Ended December 31, 2024 December 31, 2024 (000s) (000s) GAAP net income1,2 $2,256 $880 Adjustments: Mark-to-market adjustments on the derivatives related to convertible notes, net -
Slide 17: Q4 and FY 2024 Financial Summary
Q4 and FY 2024 Financial Summary LINZESS U.S. Brand Collaboration Commercial Profit & Collaboration Revenue1 Three Months Ended Twelve Months Ended December 31, 2024 December 31, 2024 (000s) (000s) LINZESS U.S. net product sales as reported by AbbVie2 $222,961 $916,281 AbbVie & Ironwood commercial c
Slide 18: Q4 and FY 2024 Financial Summary
Q4 and FY 2024 Financial Summary LINZESS U.S. Brand Collaboration Ironwood & AbbVie Total Net Profit1 Three Months Ended Twelve Months Ended December 31, 2024 December 31, 2024 (000s) (000s) LINZESS U.S. net product sales as reported by AbbVie2 $222,961 $916,281 AbbVie & Ironwood commercial costs, e
Slide 19: Thank You
A Thank YOu
Ironwood Pharmaceuticals — FY2024 Earnings Presentation on 6ix